Why Regeneron's Growth Opportunity Is Unappreciated

Regeneron Pharmaceuticals Inc REGN shares were advancing Monday following a sell-side upgrade and the news of President Donald Trump being administered its investigational COVID-19 antibody cocktail. 

The Regeneron Analyst: Cantor Fitzgerald analyst Alethia Young upgraded Regeneron shares from Neutral to Overweight and increased the price target from $624 to $690.

Related Link: The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO

The Regeneron Thesis: Regeneron shares have outperformed the broader biotech sector thanks to greater appreciation of its growth profile and a notable setback for Novartis AG's NVS wet AMD treatment Beovu in the real world, Young said in a Sunday upgrade note.

The outperformance does not reflect the allergic disease drug Dupixent's prospects as a near- and long-term growth driver, the analyst said.

Cantor estimates worldwide Dupixent sales of $6.3 billion in 2021, ahead of the $5.2-billion consensus estimate.

Expansion opportunities for Dupixent in younger patients, different indications and broader geographies should also drive commercial growth in the coming years, Young said.

With antibodies expected to emerge as an important treatment and prevention option for COVID-19, Regeneron's antibody cocktail REGN-COV2 is another unappreciated near-term revenue driver in 2021, the analyst said. The regulatory path for the antibody cocktail is uncertain, she said. 

Regeneron's oncology strategy is shaping up well, with solid monotherapy PD-1 data in non-small cell lung cancer that sets the stage for future combination work that could drive mid- to long-term growth, according to Cantor Fitzgerald. 

REGN Price Target: At last check, Regeneron shares were rallying 7.11% to $604.98.

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

Posted In: Alethia YoungCantor FitzgeraldAnalyst ColorBiotechUpgradesHealth CarePrice TargetAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.